Rate and Risk Factors of Reinfection, Recurrence, and Hospital Readmission Among SARS-Cov-2 Hospitalized Patients; a National Cohort Study
Archives of Academic Emergency Medicine,
Vol. 12 No. 1 (2024),
1 January 2024
,
Page e55
https://doi.org/10.22037/aaem.v12i1.2327
Abstract
Introduction: Reinfection and hospital readmission due to COVID-19 were significant and costly during the pandemic. This study aimed to assess the rate and risk factors of SARS-Cov-2 reinfection, recurrence, and hospital readmission, by analyzing the national data registry in Iran.
Methods: This study was a retrospective cohort conducted from March 2020 to May 2021. A census method was used to consider all of the possible information in the national Medical Care Monitoring Center (MCMC) database obtained from the Ministry of Health and Medical Education; the data included information from all confirmed COVID-19 patients who were hospitalized and diagnosed using at least one positive Polymerase Chain Reaction (PCR) test by nasopharyngeal swab specimens. Univariate and multivariable Cox regression analyses were performed to assess the factors related to each studied outcome.
Results: After analyzing data from 1,445,441 patients who had been hospitalized due to COVID-19 in Iran, the rates of overall reinfection, reinfection occurring at least 90 days after the initial infection, recurrence, and hospital readmission among hospitalized patients were 67.79, 26.8, 41.61, and 30.53 per 1000 person-years, respectively. Among all cases of hospitalized reinfection (48292 cases), 38.61% occurred more than 90 days from the initial SARS-Cov-2 infection. Getting infected with COVID-19 in the fifth wave of the disease compared to getting infected in the first wave (P<0.001), having cancer (P<0.001), chronic kidney disease (P<0.001), and age over 80 years (P<0.001) were respectively the most important risk factors for overall reinfection. In contrast, age 19-44 years (P<0.001), intubation (P<0.001), fever (P<0.001), and cough (P<0.001) in the initial admission were the most important protective factors of overall reinfection, respectively.
Conclusion: Reinfection and recurrence of COVID-19 after recovery and the rate of hospital readmission after discharge were remarkable. Advanced or young age, as well as having underlying conditions like cancer and chronic kidney disease, increase the risk of infection and readmission.
- Reinfection
- Recurrence
- Patient Readmission
- COVID-19
- Pandemics
How to Cite
References
She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clin Transl Med. 2020;9(1):19.
Al-Mandhari A, Samhouri D, Abubakar A, Brennan R. Coronavirus Disease 2019 outbreak: preparedness and readiness of countries in the Eastern Mediterranean Region. East Mediterr Health J. 2020 Feb 24;26(2):136-137.
Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020 Apr;55(4):105946.
World Health Organization. COVID 19 Public Health Emergency of International Concern (PHEIC). Global research and innovation forum: towards a research roadmap. Access July 14, 2022; Available from: https://www.who.int/publications/m/item/Covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation
WHO Coronavirus Disease (COVID-19) Situation Dashboard. 2020. Available from: https://covid19.who.int/ Accessed 14 July 2022.
Yahav D, Yelin D, Eckerle I, Eberhardt CS, Wang J, Cao B, et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin Microbiol Infect. 2021 Mar;27(3):315-318.
To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951.
Sotoodeh Ghorbani S, Taherpour N, Bayat S, Ghajari H, Mohseni P, Hashemi Nazari SS. Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: A systematic review and meta-analysis. J Med Virol. 2022;94(1):44-53.
Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJ, Simmons R, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). The Lancet. 2021;397(10283):1459-69.
Caralis P. Case Reports of COVID 19 Recurrence. J Prim Care Community Health. 2021;12:2150132720982752.
Cavanaugh AM, Thoroughman D, Miranda H, Spicer K. Suspected Recurrent SARS-CoV-2 Infections Among Residents of a Skilled Nursing Facility During a Second COVID-19 Outbreak - Kentucky, July-November 2020. MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):273-277.
Xiao AT, Tong YX, Zhang S. False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence. J Med Virol. 2020 Oct;92(10):1755-1756.
Zhang JF, Yan K, Ye HH, Lin J, Zheng JJ, Cai T. SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standards for discharge. Int J Infect Dis. 2020 Aug;97:212-214.
Parra LM, Cantero M, Morrás I, Vallejo A, Diego I, Jiménez-Tejero E, et al. Hospital readmissions of discharged patients with COVID-19. Int J Gen Med. 2020;13:1359-1366.
Loo WK, Hasikin K, Suhaimi A, Yee PL, Teo K, Xia K, et al. Systematic Review on COVID-19 Readmission and Risk Factors: Future of Machine Learning in COVID-19 Readmission Studies. Front Public Health. 2022 May 23;10:898254.
Atalla E, Kalligeros M, Giampaolo G, Mylona EK, Shehadeh F, Mylonakis E. Readmissions among patients with COVID-19. Int J Clin Pract. 2021 Mar;75(3):e13700.
Yeo I, Baek S, Kim J, Elshakh H, Voronina A, Lou MS, et al. Assessment of thirty-day readmission rate, timing, causes and predictors after hospitalization with COVID-19. J Intern Med. 2021 Jul;290(1):157-165.
Babiker A, Marvil CE, Waggoner JJ, Collins MH, Piantadosi A. The Importance and Challenges of Identifying SARS-CoV-2 Reinfections. J Clin Microbiol. 2021 Mar 19;59(4):e02769-20.
Investigative Criteria for Suspected Cases of SARS-CoV-2 Reinfection (ICR).2020. Available from : https://www.cdc.gov/coronavirus/2019-ncov/php/invest-criteria.html Access Aug,2021.
Fattahi Z, Mohseni M, Beheshtian M, Jafarpour A, Jalalvand K, Keshavarzi F, et al. Disease Waves of SARS-CoV-2 in Iran Closely Mirror Global Pandemic Trends. Arch Iran Med. 2022 Aug 1;25(8):508-522.
Reinfections and COVID-19. 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/your-health/reinfection.html Access Aug,2022.
Medić S, Anastassopoulou C, Lozanov-Crvenković Z, Vuković V, Dragnić N, Petrović V, et al. Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: A population-level observational study. Lancet Reg Health Eur. 2022 Sep;20:100453.
Lewis N, Chambers LC, Chu HT, Fortnam T, De Vito R, Gargano LM, et al. Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection. JAMA Netw Open. 2022 Jul 1;5(7):e2223917.
Piri SM, Edalatfar M, Shool S, Jalalian MN, Tavakolpour S. A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations. Infect Dis. 2021; 53(5): 315- 324.
Hoang T. Characteristics of COVID-19 Recurrence: A Systematic Review and Meta-Analysis. Ann Glob Health. 2021 Mar 24;87(1):28.
Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell. 2021 Apr 1;184(7):1671-1692.
Karimi A, Mansour Ghanaie R, Masjedi MR, Fahimzad SA, Rafiei Tabatabaei S, Armin S, et al. Development of a Novel Scoring System for Comprehensive COVID-19 Patient Evaluation: An Evidence-Based Systematic Review. Arch Pediatr Infect Dis. 2020;9(1):e110201.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733.
Falahi S, Kenarkoohi A. Sex and gender differences in the outcome of patients with COVID-19. J Med Virol. 2021;93(1):151-152.
Flacco ME, Soldato G, Acuti Martellucci C, Di Martino G, Carota R, Caponetti A, Manzoli L. Risk of SARS-CoV-2 Reinfection 18 Months After Primary Infection: Population-Level Observational Study. Front Public Health. 2022 May 2;10:884121.
Sengpiel V, Carlsson Y, Liljeqvist JÅ, Elfvin A, Fyhr IM, Lundgren A, et al. Confirmed reinfection with SARS-CoV-2 during a pregnancy: A case report. Clin Case Rep. 2022 Feb 15;10(2):e05400.
Chaubey I, Vignesh R, Babu H, Wagoner I, Govindaraj S, Velu V. SARS-CoV-2 in Pregnant Women: Consequences of Vertical Transmission. Front Cell Infect Microbiol. 2021 Sep 9;11:717104.
Purbey PK, Roy K, Gupta S, Paul MK. Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2. Mol Immunol. 2023;156:111-126.
Koupaei M, Mohamadi MH, Yashmi I, Shahabi AH, Heidari M. Clinical manifestations, treatment options, and comorbidities in COVID-19 recurrence patients: A systematic review. J Clin Lab Anal. 2022. May;36(5):e24402.
Thomson RJ, Hunter J, Dutton J, Schneider J, Khosravi M, Casement A, et al. Clinical characteristics and outcomes of critically ill patients with COVID-19 admitted to an intensive care unit in London: A prospective observational cohort study. PLoS One. 2020 Dec 15;15(12):e0243710.
Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M,et al; ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020 Aug 22;396(10250):535-544.
Boyton, R.J., Altmann, D.M. The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?. Nat Rev Immunol.2021.21, 762–768 .
Almagro P, Barreiro B, Ochoa de Echaguen A, Quintana S, Rodríguez Carballeira M, Heredia JL, et al. Risk factors for hospital readmission in patients with chronic obstructive pulmonary disease. Respiration. 2006;73(3):311-7.
Demiselle J, Calzia E, Hartmann C, Messerer DAC, Asfar P, Radermacher P, et al. Target arterial PO2 according to the underlying pathology: a mini-review of the available data in mechanically ventilated patients. Ann Intensive Care. 2021 Jun 2;11(1):88.
Mensah AA, Campbell H, Stowe J, Seghezzo G, Simmons R, Lacy J, et al. Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January,2020,and July,2021, in England. Lancet Child Adolesc Health.2022.6:384-92.
Bager P, Wohlfahrt J, Rasmussen M, Albertsen M, Krause TG. Hospitalisation associated with SARS-CoV-2 delta variant in Denmark. Lancet Infect Dis. 2021 Oct;21(10):1351.
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020 Nov 19;71(16):2027-2034.
Tavakoli A, Lotfi F, Lotfi M, Bayati M, Seif M, Salesi M, et al. COVID-19 Reinfection Rate and Related Risk Factors in Fars Province, Iran: A Retrospective Cohort Study. Iran J Med Sci. 2023;48(3):302-312.
Mohammed RN, Tamjidifar R, Rahman HS, Adili A, Ghoreishizadeh S, Saeedi H, et al. A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19). Cell Commun Signal. 2022 Jun 2;20(1):79.
- Abstract Viewed: 273 times
- pdf Downloaded: 491 times